.Attributes Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ innovative bosom cancer cells as well as active or even stable mind metastases presented regular intracranial task and wide spread efficacy of T-DXd.